Industry News
Biotechnology Industry News

Gyroscope spins the wheel again as it taps Sanofi for $60M months after ditching IPO attempt
Gyroscope spins the wheel again as it taps Sanofi for $60M months after ditching IPO attempt badams Mon, 11/08/2021 - 09:00
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca ntaylor Mon, 11/08/2021 - 06:27
Blackstone bets on Autolus’ CD19 CAR-T in $250M deal, clearing path to pivotal readout in 2022
Blackstone bets on Autolus' CD19 CAR-T in $250M deal, clearing path to pivotal readout in 2022 ntaylor Mon, 11/08/2021 - 05:26
Provention Bio, hit by AdComm rejection for lead drug, hires early research exec from Gossamer
Provention Bio, hit by AdComm rejection for lead drug, hires early research exec from Gossamer badams Mon, 11/08/2021 - 04:13
Provention Bio, hit by rejection for lead drug, hires early research exec from Gossamer
Provention Bio, hit by rejection for lead drug, hires early research exec from Gossamer badams Mon, 11/08/2021 - 04:13
Treating drug-resistant prostate cancer by exploiting tumor-suppressing RNA
Treating drug-resistant prostate cancer by exploiting tumor-suppressing RNA arlene.weintraub Fri, 11/05/2021 - 08:11
UPDATE: Pfizer’s oral COVID-19 antiviral cuts hospitalization, death by 85%, sending team barreling to FDA
UPDATE: Pfizer's oral COVID-19 antiviral cuts hospitalization, death by 85%, sending team barreling to FDA ntaylor Fri, 11/05/2021 - 07:41
UPDATE: Pfizer’s oral COVID-19 antiviral cuts hospitalization, death by 89%, sending team barreling to FDA
UPDATE: Pfizer's oral COVID-19 antiviral cuts hospitalization, death by 89%, sending team barreling to FDA ntaylor Fri, 11/05/2021 - 07:41
HitGen taps Cambridge Molecular for ‘deep learning’ drug discovery collab
HitGen taps Cambridge Molecular for 'deep learning' drug discovery collab badams Fri, 11/05/2021 - 07:22
Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing push beyond prophylactic vaccines
Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing push beyond prophylactic vaccines ntaylor Fri, 11/05/2021 - 06:50
Parkinson’s gene therapy restores responses to dopamine-boosting drug in mouse models
Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models klahucik Thu, 11/04/2021 - 17:52
Sangamo’s Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3
Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3 ntaylor Thu, 11/04/2021 - 09:21
Bayer poaches Otsuka’s chief medical officer Koenen to head up its clinical operations
Bayer poaches Otsuka's chief medical officer Koenen to head up its clinical operations badams Thu, 11/04/2021 - 08:40
After flops, Ironwood starts pipeline rebuild with liver disease deal
After flops, Ironwood starts pipeline rebuild with liver disease deal ntaylor Thu, 11/04/2021 - 08:31
Cara chief hands keys to former LEO head Posner, months after first approval in its 17-year history
Cara chief hands keys to former LEO head Posner, months after first approval in its 17-year history klahucik Wed, 11/03/2021 - 09:34
Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells
Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells aliu Wed, 11/03/2021 - 09:23
Antios, months after series B, raises a further $75M to fuel pursuit of hepatitis B cure
Antios, months after series B, raises a further $75M to fuel pursuit of hepatitis B cure ntaylor Wed, 11/03/2021 - 09:02
Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022
Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022 ntaylor Wed, 11/03/2021 - 07:23
Bristol Myers Squibb-backed Clade nabs a meaty $87M series A for cell therapy 2.0
Bristol Myers Squibb-backed Clade nabs a meaty $87M series A for cell therapy 2.0 badams Wed, 11/03/2021 - 05:36
Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers
Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers ntaylor Tue, 11/02/2021 - 08:29

